Your browser doesn't support javascript.
loading
Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.
Dias Costa, Andressa; Väyrynen, Sara A; Chawla, Akhil; Zhang, Jinming; Väyrynen, Juha P; Lau, Mai Chan; Williams, Hannah L; Yuan, Chen; Morales-Oyarvide, Vicente; Elganainy, Dalia; Singh, Harshabad; Cleary, James M; Perez, Kimberly; Ng, Kimmie; Freed-Pastor, William; Mancias, Joseph D; Dougan, Stephanie K; Wang, Jiping; Rubinson, Douglas A; Dunne, Richard F; Kozak, Margaret M; Brais, Lauren; Reilly, Emma; Clancy, Thomas; Linehan, David C; Chang, Daniel T; Hezel, Aram F; Koong, Albert C; Aguirre, Andrew J; Wolpin, Brian M; Nowak, Jonathan A.
Affiliation
  • Dias Costa A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Väyrynen SA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Chawla A; Department of Surgery, Northwestern Medicine Regional Medical Group, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Zhang J; Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.
  • Väyrynen JP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Lau MC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Williams HL; Program in Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Yuan C; Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
  • Morales-Oyarvide V; Program in Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Elganainy D; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Singh H; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Perez K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Freed-Pastor W; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Mancias JD; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Dougan SK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Wang J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Rubinson DA; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Dunne RF; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Kozak MM; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Brais L; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Reilly E; Division of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
  • Clancy T; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.
  • Linehan DC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Chang DT; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hezel AF; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Koong AC; Department of General Surgery, University of Rochester Medical Center, Rochester, New York.
  • Aguirre AJ; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.
  • Wolpin BM; Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon.
  • Nowak JA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 28(23): 5167-5179, 2022 12 01.
Article in En | MEDLINE | ID: mdl-36129461
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Carcinoma, Pancreatic Ductal Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Carcinoma, Pancreatic Ductal Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Type: Article